Skip to main content

Study Details

The Veri-T Study will test an oral investigational drug called Verdiperstat (BHV-3241) for the treatment of individuals with Semantic Variant Primary Progressive Aphasia (svPPA). Participation will include cognitive, clinical, safety, fluid biomarker, and imaging assessments for up to 6 months.

General Inclusion Criteria:

  • Age 18-85 (inclusive)
  • Diagnosed with Semantic Variant Primary Progressive Aphasia (svPPA)
  • Must have a study partner that is willing to participate as a source of information and who spends a minimum average of 10 hours per week with the participant (e.g., family member, significant other, friend, or caregiver).

General Exclusion Criteria:

  • Diagnosis of probable Alzheimer's Disease or any FTLD-associated clinical syndrome other than svPPA will exclude you from being eligible for the Veri-T Study.
Principal InvestigatorGrant, Ian MichaelGrant, Ian Michael
ClinicalTrials.gov IdentifierNCT05184569IRB number STU00216954
More Info

Follow Mesulam Center on Facebook